Medivir AB (MVIRb.F) Announces Interim Results From Cohort 2 of the COSMOS Study Evaluating Simeprevir and Sofosbuvir in HCV Patients With METAVIR Scores F3-F4
8/28/2013 10:53:25 AM
STOCKHOLM--(BUSINESS WIRE)--Regulatory news: Medivir AB (OMX: MVIR) (STO:MVIR-B) today announced interim results from the second Cohort in the ongoing COSMOS study evaluating a once daily combination of simeprevir and sofosbuvir in hard to cure hepatitis C (HCV) patients. SVR4 results from the 12 week arms of Cohort 2, including treatment naïve or previous null responder HCV patients all with METAVIR score F3-F4 were reported. Treatment for 12 weeks with simeprevir and sofosbuvir, with or without ribavirin, led to SVR4 rates of 96% and 100%, respectively. Interim results from Cohort 1 of the COSMOS study, which include only prior null responder HCV patients (METAVIR F0-F2) have been reported earlier and demonstrated SVR8 rates of 96% and 93% after 12 weeks treatment simeprevir and sofosbuvir with and without ribavirin, respectively.
Help employers find you! Check out all the jobs and post your resume.
comments powered by